These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9000585)

  • 1. Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity.
    Vaisman A; Varchenko M; Said I; Chaney SG
    Cytometry; 1997 Jan; 27(1):54-64. PubMed ID: 9000585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of cisplatin and ICI 182,780 on estrogen receptor negative ovarian cancer cells: cell cycle and cell replication rate perturbation, chromatin texture alteration and apoptosis induction.
    Ercoli A; Battaglia A; Raspaglio G; Fattorossi A; Alimonti A; Petrucci F; Caroli S; Mancuso S; Scambia G
    Int J Cancer; 2000 Jan; 85(1):98-103. PubMed ID: 10585591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
    Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell cycle perturbations in cisplatin-sensitive and resistant human ovarian carcinoma cells following treatment with cisplatin and low dose rate irradiation.
    Wilkins DE; Ng CE; Raaphorst GP
    Cancer Chemother Pharmacol; 1997; 40(2):159-66. PubMed ID: 9182838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-proliferative activity and mechanism of action of titanocene dichloride.
    Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ
    Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines.
    Brown R; Clugston C; Burns P; Edlin A; Vasey P; Vojtĕsek B; Kaye SB
    Int J Cancer; 1993 Oct; 55(4):678-84. PubMed ID: 8406999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic isothiocyanate indole-3-ethyl isothiocyanate (homoITC) enhances sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to cisplatin.
    Stehlik P; Paulikova H; Hunakova L
    Neoplasma; 2010; 57(5):473-81. PubMed ID: 20568902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
    Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
    Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines.
    Gibb RK; Taylor DD; Wan T; O'Connor DM; Doering DL; Gerçel-Taylor C
    Gynecol Oncol; 1997 Apr; 65(1):13-22. PubMed ID: 9103385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
    Delmastro DA; Li J; Vaisman A; Solle M; Chaney SG
    Cancer Chemother Pharmacol; 1997; 39(3):245-53. PubMed ID: 8996528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
    Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
    Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines.
    Ormerod MG; O'Neill C; Robertson D; Kelland LR; Harrap KR
    Cancer Chemother Pharmacol; 1996; 37(5):463-71. PubMed ID: 8599870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control.
    Poulain L; Lincet H; Duigou F; Deslandes E; Sichel F; Gauduchon P; Staedel C
    Int J Cancer; 1998 Nov; 78(4):454-63. PubMed ID: 9797134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
    Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
    Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
    Yan X; Fraser M; Qiu Q; Tsang BK
    Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.